Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.
Department of Respiratory Medicine, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
Cancer Sci. 2021 May;112(5):2006-2019. doi: 10.1111/cas.14821. Epub 2021 Apr 2.
Liquid biopsy analyzes the current status of primary tumors and their metastatic regions. We aimed to develop an optimized protocol for single-cell sequencing of floating tumor cells (FTCs) in pleural effusion as a laboratory test. FTCs were enriched using a negative selection of white blood cells by a magnetic-activated cell sorting system, and CD45-negative and cytokeratin-positive selection using a microfluidic cell separation system with a dielectrophoretic array. The enriched tumor cells were subjected to whole-genome amplification (WGA) followed by genome sequencing. The FTC analysis detected an EGFR exon 19 deletion in Case 1 (12/19 cells, 63.2%), and EML4-ALK fusion (17/20 cells, 85%) with an alectinib-resistant mutation of ALK (p.G1202R) in Case 2. To eliminate WGA-associated errors and increase the uniformity of the WGA product, the protocol was revised to sequence multiple single FTCs individually. An analytical pipeline, accurate single-cell mutation detector (ASMD), was developed to identify somatic mutations of FTCs. The large numbers of WGA-associated errors were cleaned up, and the somatic mutations detected in FTCs by ASMD were concordant with those found in tissue specimens. This protocol is applicable to circulating tumor cells analysis of peripheral blood and expands the possibility of utilizing molecular profiling of cancers.
液体活检分析原发性肿瘤及其转移部位的当前状态。我们旨在开发一种优化的方案,用于对胸腔积液中的游离肿瘤细胞(FTCs)进行单细胞测序,作为实验室检测。通过磁激活细胞分选系统对白细胞进行阴性选择,使用带有介电泳阵列的微流控细胞分离系统对 CD45 阴性和细胞角蛋白阳性进行选择,从而富集 FTCs。对富集的肿瘤细胞进行全基因组扩增(WGA),然后进行基因组测序。FTC 分析在病例 1 中检测到 EGFR 外显子 19 缺失(19 个细胞中的 12 个,63.2%),在病例 2 中检测到 EML4-ALK 融合(20 个细胞中的 17 个,85%),并伴有 ALK(p.G1202R)耐药突变。为了消除 WGA 相关错误并提高 WGA 产物的均匀性,修订了方案,以便单独对多个单个 FTC 进行测序。开发了一种分析管道,即准确的单细胞突变检测器(ASMD),用于鉴定 FTC 的体细胞突变。大量的 WGA 相关错误被清理掉,ASMD 在 FTC 中检测到的体细胞突变与在组织标本中发现的突变一致。该方案适用于外周血循环肿瘤细胞的分析,并扩大了利用癌症分子谱进行分析的可能性。